Magenta Therapeutics

Equities

MGTA

US55910K1088

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-23 pm EST			5-day change	1st Jan Change
52.33 ^USD	-0.82%		+18.66%	+367.50%

23-09-11	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
23-09-10	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI

Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

Published on 05/15/2023 at 04:07 pm EDT

S&P Capital IQ

MAGENTA THERAPEUTICS

-0.82%

Magenta Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 29.17 million compared to USD 22.95 million a year ago. Basic loss per share from continuing operations was USD 0.48 compared to USD 0.39 a year ago.

Latest news about Magenta Therapeutics

23-09-11	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
23-09-10	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI
23-08-31	North American Morning Briefing : PCE Inflation -2-	DJ
23-08-24	North American Morning Briefing : Nasdaq Futures -2-	DJ
23-08-17	North American Morning Briefing : Treasury Yields Keep Pushing Higher	DJ
23-08-10	North American Morning Briefing : Attention Turns -2-	DJ
23-08-03	Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-06-23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index	CI
23-06-23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index	CI
23-06-23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index	CI
23-06-23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index	CI
23-05-19	Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer	CI
23-05-15	Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-05-15	North American Morning Briefing : Hopes Build for -3-	DJ
23-05-03	Dianthus Therapeutics, Inc., Magenta Therapeutics, Inc. - M&A Call
23-05-02	Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction.	CI
23-04-06	Magenta Therapeutics, Inc. Enters into Sublease Termination and Release Agreement with Novartis Institutes for Biomedical Research, Inc	CI
23-03-21	North American Morning Briefing : Stock Futures -2-	DJ
23-03-14	North American Morning Briefing : CPI Print Takes -3-	DJ
23-03-07	North American Morning Briefing : Stocks Seen on -2-	DJ
23-02-28	HC Wainwright Initiates Magenta Therapeutics at Neutral	MT
23-02-07	Magenta Therapeutics, Inc. Announces Management Changes	CI
23-02-07	Magenta Therapeutics, Inc. Announces the Resignation of Jason Gardner, Chief Executive Officer	CI
23-02-03	Rapid January Jobs Growth and Weak Tech Earnings Weigh on US Equity Futures	MT
23-02-03	Top Premarket Gainers	MT

Chart Magenta Therapeutics

Duration

Period

MGTA: Dynamic Chart

Company Profile

Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.

Employees

Sector

More about the company